Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KAT7 | O95251 | 5/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 5/20 | 0.45 |
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
| ▸ | KAT6B | Q8WYB5 | 2/20 | 0.42 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.42 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29652503 | 1.00 | KMT2A (0.58) | KMT2AMEN1MAPTPOLBPKM | |
| SCHEMBL29652449 | 0.84 | MAPT (0.48) | KMT2AMEN1MAPTKAT7KAT6A | |
| SCHEMBL21609218 | 0.84 | MAPT (0.48) | KMT2AMEN1MAPTKAT7KAT6A | |
| SCHEMBL29652598 | 0.81 | ALDH1A1 (0.47) | KMT2AMEN1POLBKAT6A | |
| SCHEMBL21609222 | 0.81 | ALDH1A1 (0.47) | KMT2AMEN1POLBKAT6A | |
| SCHEMBL21596862 | 0.80 | EDNRB (0.47) | KMT2AMAPTPOLBKAT7KAT6A | |
| SCHEMBL29652441 | 0.79 | KMT2A (0.43) | KMT2AMEN1MAPTKAT7KAT6A | |
| SCHEMBL21609217 | 0.79 | EDNRB (0.46) | KMT2AMEN1 | |
| SCHEMBL21609216 | 0.79 | KMT2A (0.43) | KMT2AMEN1MAPTKAT7KAT6A | |
| SCHEMBL29652497 | 0.79 | EDNRB (0.46) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4335439-A2 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| US-20200039945-A1 | Compounds | CTXT PTY LIMITED (AU) | 2020-02-06 | — | — | US | disclosed |
| US-20200039945-A1 | Compounds | CTXT PTY LIMITED (AU) | 2020-02-06 | — | — | US | disclosed |
| WO-2019243491-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153710-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | KMT2A 4165/4885MEN1 122/4885MAPT 1135/4885 |
| US-20200039945-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | KMT2A 4165/4885MEN1 121/4885MAPT 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.